腺苷蛋氨酸治疗乙型肝炎后肝硬化临床疗效观察

目的 观察腺苷甲硫氨酸(俗名蛋氨酸)治疗乙型肝炎(简称乙肝)后肝硬化的疗效.方法 选择乙肝后肝硬化患者60例,其中治疗组30例,对照组30例.血清总胆红素(TBIL)均大于55μmol/L,平均(102.12±22.31) μmol/L.治疗组TBIL为(98.23±17.50)μmol/L,对照组为(113.21±17.70) μmol/L,差异无统计学意义(P＞0.01).治疗组予以腺苷蛋氨酸(1000mg,静脉滴注,每天1次)及多烯磷脂酰胆碱(465 mg,静脉滴注,每天1次)联合治疗,疗程2周;对照组用多烯磷脂酰胆碱(465 mg,静脉滴注,每天1次)治疗,疗程2周.结果 治疗2周后,治疗组患者TBIL由(98.23±17.50)μmol/L降至(63.56±12.47)μmol/L,差异有统计学意义(P＜0.05)；对照组TBIL由(113.21±17.70) μmol/L降至(108.60±24.38)μmol/L,与治疗组比较,差异有统计学意义(P＜0.05).且治疗组未见明显不良反应.结论 腺苷蛋氨酸治疗乙肝后肝硬化安全、有效,退黄效果显著.

Clinical efficacy observation of S-adenosyl-L-methionine in treating liver cirrhosis after hepatitis B

Objective To observe the therapeutic efficacy of S-adenosyl-L-methionine （SALM） on liver cirrhosis after hepatitis B. Methods 60 patients with liver cirrhosis after hepatitis B, serum total bilirubin （TBIL）〉55 μmol/L, average （102.12±22.31 ）μmol/L,were selected and divided into two groups,30 cases in each group. TBIL was （98.23±17.50）μmol/L in the treat- ment group and （113.21 ±17.70）μmol/L in the control group without statistical difference （P〉O.05）. The treatment group was given SALM 1 000 mg and polyene phosphatidyl choline 465 mg,by intravenous drip,once daily,for 2 weeks,while the control group was treated with polyene phosphatidyl choline 465 mg by intravenous drip, once daily for 2 weeks. Results After 2-week treatment, the serum TBIL levels in the SALM group were decreased from （98.23± 17.50）Ixmol/L to （63.56±12.47 ）txmol/L with statistical difference （ P〈0.05 ）. The TBIL levels in the control group were decreased from （ 113.21 ±17.70 ） μmol/L to （ 108.60±4.3 ） μmol/L, showing statistical difference compared with the treatment group （P〈0.05）. No apparent adverse reactions were found in the treatment group. Conclusion SALM is safe and effective in the treatment of liver cirrhosis after hepatitis B, especially with obvious anti-aurigo effects.